Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > Online
COMMENTARY   Open Access     Cite

Semaglutide in obesity-related knee osteoarthritis: Interpreting STEP 9 and implications for practice

  • 1.

    Department of Orthopedics and Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

  • 2.

    Department of Orthopedics, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 XianXia Road, Shanghai 200336, China

  • 3.

    Shanghai Yuhui Pharmaceutical Technology (Group) Co., Ltd., Shanghai 201203, China

  • 4.

    Department of Physiology, Shihezi University School of Medicine, Shihezi 832000, China

  • 5.

    Department of Orthopedics, Shanghai Changzheng Hospital, Shanghai 200003, China

  • 6.

    These authors contributed equally

    • Show all affliationsShow less
More Information
The Innovation Medicine  https://doi.org/10.59717/j.xinn-med.2026.100244  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Bliddal H., Bays H., Czernichow S., et al. (2024). Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391:1573-1583. DOI:10.1056/NEJMoa2403664

    View in Article Google Scholar

    [2] Zhu H., Zhou L., Wang Q., et al. (2023). Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: Findings from the Shanghai Osteoarthritis Cohort. Ann. Rheum. Dis. 82:1218-1226. DOI:10.1136/ard-2023-223845

    View in Article Google Scholar

    [3] Zhang W., Robertson J., Jones A.C., et al. (2008). The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 67:1716−1723. DOI:10.1136/ard.2008.092015

    View in Article CrossRef Google Scholar

    [4] Wilding J.P.H., Batterham R.L., Calanna S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384:989−1002. DOI:10.1056/NEJMoa2032183

    View in Article CrossRef Google Scholar

    [5] Chang Y., Chi K.Y., Song J., et al. (2025). Association of GLP-1 receptor agonist use with risk of lumbar degenerative disease and spine surgery in patients with type 2 diabetes: A propensity score-matched cohort study. Global Spine J. 16:1418−1422. DOI:10.1177/21925682251383170

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Ren L., Xiao Y., Liu X., et al. (2026). Semaglutide in obesity-related knee osteoarthritis: Interpreting STEP 9 and implications for practice. The Innovation Medicine 4:100244. https://doi.org/10.59717/j.xinn-med.2026.100244
    Ren L., Xiao Y., Liu X., et al. (2026). Semaglutide in obesity-related knee osteoarthritis: Interpreting STEP 9 and implications for practice. The Innovation Medicine 4:100244. https://doi.org/10.59717/j.xinn-med.2026.100244

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(252) PDF downloads(57)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.